Invesaro

Stocks NUMD Financial statements

Financial statements

Nu-Med Plus, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Nu-Med Plus, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue00000
General and administrative0.060.060.130.080.060.030.030.030.030.02
Operating expenses1.220.471.171.021.990.840.180.120.060.05
Operating income-1.22-0.47-1.17-1.02-1.99-0.84-0.18-0.12-0.06-0.05
Interest expense-0.02-0.02-0.020.020.0100.010.010.01
Interest income00000
Other non-operating income-0.01-0.01-0.01
Pre-tax income3.761.4-0.31-0.270.52-0.83-0.13-0.13-0.07-0.06
Income tax00000
Net income9.653.58-1.19-1.04-2.01-0.83-0.13-0.13-0.07-0.06
EBITDA-1.22-0.45-1.15-1.01-1.98-0.83-0.18-0.12-0.06-0.05
EPS, basic0.260.10-0.03-0.02-0.04-0.010.000.000.000.00
EPS, diluted0.130.05-0.03-0.02-0.04-0.010.000.000.000.00
Shares, basic (weighted)37.237.541.845.554.573.48081.783.583.5
Shares, diluted (weighted)7571.941.845.554.573.48081.783.583.5

Balance sheet

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash and equivalents0.010.350.170.010.190.010.070.0100
Other current assets0.010.220.010.350.010.010.010.010.01
Total current assets0.010.360.390.010.540.010.080.010.010.01
Property, plant and equipment0.020.050.040.020.0100
Lease right-of-use assets00.010.010.01
Total assets0.040.410.420.050.560.020.080.010.010.01
Accounts payable0.0100.010.040.030.030.010.010.040.05
Accrued liabilities0.070.080.020.010.030.0900.010.010.02
Total current liabilities4.470.330.370.420.080.150.140.160.220.28
Long-term debt00.010
Total liabilities4.470.340.370.420.090.150.140.160.220.28
Total debt0
Paid-in capital3.583.734.855.858.439.369.569.599.599.59
Retained earnings-8.08-4.5-5.69-6.73-8.74-9.57-9.7-9.82-9.89-9.95
Shareholders' equity-4.440.070.05-0.370.47-0.13-0.06-0.15-0.22-0.27
Total equity-4.440.070.05-0.370.47-0.13-0.06-0.15-0.22-0.27
Total liabilities and equity0.040.410.420.050.560.020.080.010.010.01
Shares outstanding37.237.641.344.55179.381.383.583.583.5

Cash flow statement

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Net income9.653.58-1.19-1.04-2.01-0.83-0.13-0.13-0.07-0.06
Depreciation and amortization0.010.010.010.010.010.010000
Stock-based compensation000.230.20.960.20.040.04
Change in payables-0-0.010.010.03-0.010.03-0.0100.030.01
Cash from operations-0.18-0.43-0.47-0.57-0.41-0.21-0.04-0.07-0-0.05
Capital expenditures00.010
Cash from investing00-0.0100
Stock issued0.1100.20.03
Cash from financing0.160.770.290.410.60.030.10.05
Net change in cash-0.020.34-0.18-0.160.18-0.180.06-0.07-0-0
Free cash flow-0.43-0.46-0.57
Interest paid000000
Income taxes paid00000

Key metrics

Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $0.01 on September 25, 2026.

Profitability

MetricValueHow it is calculated
Return on assets (ROA)-650.1%Net income / average total assets.

Growth

MetricValueHow it is calculated
Total assets growth, 1y-15.6%Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y-53.7%Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y-57.3%Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y0.0%Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y1.5%Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y8.9%Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

MetricValueHow it is calculated
Current ratio0.03xCurrent assets / current liabilities.
Quick ratio0.00x(Cash + short-term investments + receivables) / current liabilities.
Cash ratio0.00x(Cash + short-term investments) / current liabilities.
Debt / assets0.0%Total debt / total assets.
Liabilities / assets3,529.0%Total liabilities / total assets.
Net debt-$661.0Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage-6.77xOperating income / interest expense.
Working capital-$271.3KCurrent assets - current liabilities.
Tangible book value-$271.3KShareholders' equity - goodwill - intangible assets.

Per share

MetricValueHow it is calculated
EPS, diluted$0.00Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic$0.00Net income per basic share, as reported (split-adjusted).
Operating cash flow per share-$0.00Cash from operations / diluted weighted shares.
Book value per share-$0.00Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share-$0.00Tangible book value / shares outstanding.
Cash per share$0.00(Cash + short-term investments) / shares outstanding.

Valuation

MetricValueHow it is calculated
Market cap$1.2MShare price x shares outstanding.
Enterprise value$1.2MMarket cap + total debt - cash - short-term investments.
Earnings yield-4.6%Net income / market cap (the inverse of P/E).
Was Nu-Med Plus, Inc. profitable in fiscal 2025?

No. It reported a net loss of $56.2K.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Nu-Med Plus, Inc.